Medical Devices

Aussie biotech ENA Respiratory secures crucial US patents for its novel immune modulator, signaling a major strategic move in the multi-billion dollar fight against COPD.

With exploration complete, new state laws in place, and a fortified land position, Pulsar Helium is fast-tracking its Topaz project to production.

A massive 15,000-patient study on an existing therapy could upend respiratory care, combat antibiotic resistance, and deliver a bottom-line windfall.

A breakthrough publication identifies a novel protein, LanCL1, as a key target for neuropathic pain, validating a new class of drugs for millions of sufferers.

Sanofi's latest FDA nod for Tzield isn't just a new drug approval; it's a strategic shift from symptom management to disease modification in Type 1 Diabetes.

Australian biotech Gelteq has a gel that makes bitter medicine taste good to dogs. It's more than a pet owner's dream—it's a strategic move in a $47B market.

A Chicago jury's landmark verdict reveals how a single day's delay can lead to a lifetime of paralysis, questioning the very fabric of patient safety.

A silent barrier in diabetes care, 'clinical inertia,' leaves patients at risk. New research shows how empowering pharmacists with targeted education can turn the tide.

Echo IQ partners with Mayo Clinic to test its AI for cardiac risk in cancer patients, a key move for validation in the burgeoning cardio-oncology sector.

MBX Biosciences' new one-year data for canvuparatide isn't just a clinical win; it's a calculated move to dominate a billion-dollar market left vacant.

Kymera Therapeutics reports promising data for KT-621, a first-in-class oral drug that removes a key inflammatory protein, not just block it.

With a new CMO, Get A Drip is capitalizing on the longevity trend. But as it expands, it faces questions on scientific rigor and regulatory oversight.

A new FDA-designated device aims to filter a deadly protein from the blood of sepsis patients. Can this novel approach finally conquer a global health crisis?

Abridge unveils a sweeping AI platform to combat clinician burnout and mend a fragmented system by linking care delivery, payment, and research.

With $75M and a playbook from Danaher's founder, Talon Precision aims to rebuild America's industrial base, one high-tech machine shop at a time.

A new FDA-approved therapy from Boehringer Ingelheim and a liquid biopsy from Guardant Health offer the first targeted initial treatment for HER2-mutant NSCLC.

A Tulsa jury found a doctor negligent, awarding $15M to a girl left with severe brain damage after a missed diagnosis of bacterial meningitis as an infant.

Groundbreaking research on new drug classes, the gut-brain axis, and personalized medicine will be unveiled at the upcoming American Headache Society meeting.

A fivefold increase in one year, THINK Surgical’s miniature robot is reshaping orthopedics with its unique open platform and powerful industry partnerships.

Therini Bio's novel drug THN391 enters trials, targeting inflammation in diabetic eye disease, while a next-gen combo therapy aims to redefine care.